Immunotherapy (Investigational Checkpoint)
16 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Immunotherapy (Investigational Checkpoint) (16)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Acasunlimab |
Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist | Solid Tumour | ||
|
Molecule
Acasunlimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist |
||||
Bavituximab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Bavituximab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Belrestotug |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Belrestotug
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
BMS-986258 |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
BMS-986258
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Cobolimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Cobolimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Domvanalimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Domvanalimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Eftilagimod Alfa |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Eftilagimod Alfa
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
EOS-448 (Belrestotug) |
TIGIT Inhibitor | Solid Tumour | ||
|
Molecule
EOS-448 (Belrestotug)
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
TIGIT Inhibitor |
||||
Etigilimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Etigilimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Favezelimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Favezelimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Ociperlimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Ociperlimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Rilvegostomig |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Rilvegostomig
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
AcasunlimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist |
|
BavituximabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
BelrestotugImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
BMS-986258Immunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
CobolimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
DomvanalimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
Eftilagimod AlfaImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
EOS-448 (Belrestotug)Immunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
TIGIT Inhibitor |
|
EtigilimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
FavezelimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
OciperlimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
RilvegostomigImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|